| scholarly article | Q13442814 |
| P50 | author | Jeanne Lusher | Q14084239 |
| Steven R. Lentz | Q56920970 | ||
| P2093 | author name string | Marilyn J Manco-Johnson | |
| Kate T Montgomery | |||
| Amy D Shapiro | |||
| Kenneth D Friedman | |||
| Cindy Leissinger | |||
| Raymond G Hoffmann | |||
| W Keith Hoots | |||
| Daniel B Bellissimo | |||
| Ralph A Gruppo | |||
| David Lillicrap | |||
| Margaret V Ragni | |||
| Robert R Montgomery | |||
| Anne C Goodeve | |||
| Ian R Peake | |||
| Joan Cox Gill | |||
| Lisa N Boggio | |||
| Mahua Dasgupta | |||
| Pamela A Christopherson | |||
| Paula D James | |||
| Rupa A Udani | |||
| Sandra L Haberichter | |||
| Thomas C Abshire | |||
| Veronica H Flood | |||
| P2860 | cites work | Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project | Q30848055 |
| Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor | Q34022444 | ||
| The effect of ABO blood group on the diagnosis of von Willebrand disease. | Q34180946 | ||
| Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association | Q34319603 | ||
| Detection limit of intragenic deletions with targeted array comparative genomic hybridization | Q34530570 | ||
| The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study | Q34595035 | ||
| Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. | Q34667787 | ||
| Von Willebrand disease type 1: a diagnosis in search of a disease | Q34986170 | ||
| Crucial role for the VWF A1 domain in binding to type IV collagen | Q35252688 | ||
| Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. | Q35848737 | ||
| VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population | Q35849223 | ||
| Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage | Q35995241 | ||
| Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease | Q36369902 | ||
| Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). | Q36658007 | ||
| The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels | Q37043558 | ||
| von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). | Q37100261 | ||
| Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. | Q37480494 | ||
| The evolution and value of bleeding assessment tools | Q37484489 | ||
| Bleeders, bleeding rates, and bleeding score | Q38117731 | ||
| Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing | Q38252010 | ||
| Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. | Q38413638 | ||
| Quantitative impact of using different criteria for the laboratory diagnosis of type 1 von Willebrand disease | Q44604269 | ||
| Prevalence of von Willebrand disease in children: a multiethnic study | Q45090528 | ||
| Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease | Q45145414 | ||
| The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease | Q45864717 | ||
| A sensitive ELISA for von Willebrand factor (vWf:Ag). | Q50709144 | ||
| Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. | Q51897040 | ||
| Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). | Q51918283 | ||
| Ristocetin: a means of differentiating von Willebrand's disease into two groups | Q54269157 | ||
| The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study | Q56224977 | ||
| Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD) | Q59511666 | ||
| A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD) | Q59511676 | ||
| Slippery criteria for von Willebrand disease type 1 | Q60265857 | ||
| CLEC4MandSTXBP5gene variations contribute to von Willebrand factor level variation in von Willebrand disease | Q62107228 | ||
| von Willebrand disease and aging: an evolving phenotype | Q62107242 | ||
| Epidemiological investigation of the prevalence of von Willebrand's disease | Q68812162 | ||
| von Willebrand factor is an acute phase reactant in man | Q69058730 | ||
| A semiautomatic one-stage factor 8 assay with a commercially prepared standard | Q72210856 | ||
| An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease | Q79323709 | ||
| An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation | Q79969305 | ||
| Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation | Q79969309 | ||
| ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders | Q84564581 | ||
| Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients | Q84748962 | ||
| The prevalence of symptomatic von Willebrand disease in primary care practice | Q84814868 | ||
| Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin | Q87719895 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2481-2488 | |
| P577 | publication date | 2016-02-09 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States | |
| P478 | volume | 127 |
| Q38840603 | A diagnostic approach to mild bleeding disorders |
| Q47350762 | Advances in the diagnosis and treatment of Von Willebrand disease |
| Q49989077 | Advances in the diagnosis and treatment of Von Willebrand disease. |
| Q92273594 | Bleeding Symptoms and von Willebrand Factor Levels: 30-Year Experience in a Tertiary Care Center |
| Q57094753 | Common sequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD |
| Q38690381 | Controversies in the diagnosis of Type 1 von Willebrand disease |
| Q90670328 | Current approaches to diagnostic testing in von Willebrand Disease |
| Q57095004 | Current issues in diagnosis and treatment of von Willebrand disease |
| Q90628838 | Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding |
| Q47416217 | Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels |
| Q39322760 | Flow chamber and microfluidic approaches for measuring thrombus formation in genetic bleeding disorders |
| Q93092084 | Genetic Variation in the von Willebrand Factor Gene in Swedish von Willebrand Disease Patients |
| Q91675224 | Genetic regulation of plasma von Willebrand factor levels in health and disease |
| Q48123953 | Genetic variation in the C-type lectin receptor CLEC4M in type 1 von Willebrand Disease patients |
| Q93196766 | How I manage severe von Willebrand disease |
| Q97551370 | Low VWF: insights into pathogenesis, diagnosis, and clinical management |
| Q47165791 | Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients. |
| Q39027900 | New treatment approaches to von Willebrand disease. |
| Q47793791 | Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels |
| Q45871569 | The Association of Aging With Von Willebrand Factor Levels and Bleeding Risk in Type 1 Von Willebrand Disease. |
| Q64890963 | The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity. |
| Q57094780 | Von Willebrand disease in the United States: perspective from the Zimmerman program |
| Q30240214 | What have we learned from large population studies of von Willebrand disease? |
| Q91959533 | von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD |
Search more.